The assessment and diagnostic workup of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) is evolving, as discussed…
Browsing: Non-Small Cell Lung Cancer
Enriqueta Felip, MD, PhD, of Vall dHebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small…
Dr. Gerard Silvestri, Medical University of South Carolina, describes the steps necessary to work up a lung cancer diagnosis, from…
Steroids were previously administered as a form of treatment for many different conditions, including cancer. However, the previous usage of…
The use of sequential single-gene testing to detect genomic alterations in metastatic non-small cell lung cancer (NSCLC) can be costly,…
The KEYNOTE-189 ( NCT02578680) trial investigated the effects of adding pembrolizumab to cisplatin and pemetrexed in patients with non-small cell…
The ATLANTIC trial (NCT02087423) is currently underway to determine the effects of durvalumab on patients with advanced non-small cell lung…
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses smoking, asbestos, radon and other risk factors for lung cancer.
Benjamin Philip Levy, MD, talks about the data from Keynote 189, specifically, how chemotherapy should be combined with immunotherapy in…
Benjamin Philip Levy, MD, explains whether every non-small cell lung cancer (NSCLC) patient should be tested for PD-L1 expression and…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, David Carbone, MD, PhD, of Ohio…
Mohammad Jahanzeb, MD, FACP, explains what he might do in sequencing therapies as a result of Keynote 189 and Keynote…
Mohammad Jahanzeb, MD, FACP, explains the significance of Keynote 42 from Annual Meeting 2018.
Mohammad Jahanzeb, MD, FACP, shares his thoughts on the continuation of pemetrexed maintenance after treatment of the patient with carboplatin,…
Mohammad Jahanzeb, MD, FACP, explains the results of Keynote 189, PDL-1 expression and patient selection at Annual Meeting 2018.
David R. Gandara, MD, talks about the benefits of using Cyramza® (ramucirumab) plus docetaxel verus docetaxel alone in 2nd line…
David R. Gandara, MD, explains drug sequencing as a result of Keynote 189 and 42 results at Annual Meeting 2018.
Joan Schiller, MD, talks about the Keynote trials presented and whether they will impact her choice of therapy for squamous…
David R. Gandara, MD, explains what will change about patient selection as a result of Keynote 42 at Annual Meeting…
Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting…
David R. Gandara, MD, talks about continuing pemextrexed maintenance
David R. Gandara, MD, explains whether Keynote 189 impacted view of PDL-1 expression and patient selection at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, discusses if patient selection will change as a result of Keynote 42
David R. Gandara, MD, shares exciting new developments in lung cancer
Roy S. Herbst, MD, PhD, shares his thoughts on whether to continue pemetrexed maintenance after successful treatment of the patient…
Edgardo S. Santos, MD, FACP, explains the benefits of docetaxel plus ramucirumab versus docetaxel alone during 2nd line non-small cell…
Joan Schiller, MD, shares her thoughts regarding the results of Keynote 42 presented at the 2018 Annual Meeting and how…
Roy S. Herbst, MD, PhD, shares his thoughts on whether Keynote 189 impacted view of PDL-1 expression and patient selection.
Edgardo S. Santos, MD, FACP, shares his opinion on continued pemetrexed maintenance.
Joan Schiller, MD, shares her opinion on continuing pemetrexed maintenance after successful treatment with carboplatin, pemetrexed & pembrolizumab
Joan Schiller, MD, shares Keynote 189 and whether the data impacts her view of PDL-1 expression and patient selection at…
Edgardo S. Santos, MD, FACP, talks about whether Keynote 189 in metastatic non-small cell lung cancer (NSCLC) has impacted his…
Dr. Jack West reviews the remarkable results of the NEJ009 trial that tested the combination of carboplatin/pemetrexed with gefitinib as…
Marianne Nicolson, MD, FRCP, BSc, MBChB, of NHS Grampian, Aberdeen, UK, gives an overview of a session discussing lung cancer…
Mariam Jamal-Hanj, BSc, MBBS, PhD, of University College London, London, UK, discusses her talk regarding intra-tumor heterogeneity within lung cancer…
Dr. Jack West reviews results from ARCHER-1050, a trial of dacomitinib vs. gefitinib, in EGFR mutation-positive NSCLC, asks whether the…
Lung cancer is the leading cause of cancer mortality in the United States, and low-dose CT scans are advised as…
Dr. Jack West discusses results and the significance of two important Japanese trials that test the combination of erlotinib (Tarceva)…
An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize…
The implementation of biomarkers into clinical practice is an exciting area of research, and the field of non-small cell lung…
The management of patients with metastatic non-small cell lung cancer (NSCLC) is a field which has seen drastic improvement in…
Liviu Niculescu, MD PhD, explains Frontline Trials to Show if Alunbrig is Superior Figure What is the Best Sequencing for…
Liviu Niculescu, MD PhD, explains Patients Have Other Companies & Research Groups Working with Colleagues to Advance Life of Patients…
Liviu Niculescu, MD PhD, explains Newly Diagnosed Patients with ALK-Positive Disease Are Being Randomized with Alunbrig at Annual Meeting 2018
Liviu Niculescu, MD PhD, Alunbrig – Drug for ALK-Positive Lung Cancer 56% Overall Response Rate at Annual Meeting 2018
Dr. Nasser Hanna, Indiana University Health, considers the use of induction or consolidation chemotherapy for unresectable stage III NSCLC.
Dr. Nasser Hanna, Indiana University Health, discusses the development of chemoradiation as a standard of care for unresectable stage III…
Dr. Nasser Hanna, Indiana University Health, reviews efforts to utilize targeted therapies as consolidation after chemoradiation in locally advanced NSCLC
Dr. Nasser Hanna, Indiana University Health, lists chemo regiments appropriate for use with radiation in locally advanced NSCLC.